| Stereochemistry | RACEMIC |
| Molecular Formula | C21H31NO3 |
| Molecular Weight | 345.4757 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NCC(O)COC1=C2CC3(CCCCC3)C(=O)C2=CC=C1
InChI
InChIKey=YLBMSIZZTJEEIO-UHFFFAOYSA-N
InChI=1S/C21H31NO3/c1-20(2,3)22-13-15(23)14-25-18-9-7-8-16-17(18)12-21(19(16)24)10-5-4-6-11-21/h7-9,15,22-23H,4-6,10-14H2,1-3H3
| Molecular Formula | C21H31NO3 |
| Molecular Weight | 345.4757 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Spirendolol (LI 32-468) is a β adrenergic receptor antagonist. It possesses high affinity for metabolic beta-adrenoreceptors which mediate glycogenolysis that is 100 times more potent than propranolol. In human volunteer studies, a single dose of 2 mg LI 32-468 elicited virtually no cardiac beta-adrenoreceptor blockade (predominantly beta-1), whereas a maximal metabolic beta-adrenoreceptor blocking effect (beta-2) was demonstrated. Spirendolol was a potent inhibitor of ocular beta-adrenoceptors, with a 9-12 fold selectivity over inhibition of beta-adrenoceptors in cardiac tissue. When applied topically, Spirendolol was more effective than timolol in decreasing intraocular pressure in normal albino rabbits.
CNS Activity
Approval Year
PubMed
Sample Use Guides
In order to study the mode of action of beta-adrenoreceptor antagonists in essential tremor the efficacy of single oral doses of 2, 4 and 10 mg Spirendolol (LI 32-468) was compared with a single oral dose of 120 mg propranolol in a randomised, double blind, placebo controlled trial.
Route of Administration:
Oral
